Daewoong Pharmaceutical discovers new YAP1/TEAD interaction inhibitors

Feb. 24, 2025

Daewoong Pharmaceutical Co. Ltd. has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 27, 2025

Lost in trans-lation? Trump’s mouse charge doesn’t click

BioWorld

U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example...

FDA says changes in Dexcom G6, G7 sensors constitute misbranding

BioWorld MedTech

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures...

Gene therapy efforts active, despite low Bluebird, 2seventy bids

BioWorld

Bristol Myers Squibb Co.’s decision this week to snag Bluebird Bio Inc. spinout 2seventy Bio Inc. for $102 million net – just weeks after investors bid $30...